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Previewsmetabolism, which was reverted by anti-
sense oligonucleotides to target C9orf72
mRNA. Taken together, these studies
reveal that iPSC-derived motoneurons
from ALS patients develop common path-
ological features resembling early stages
of the disease that could be used to test
novel therapeutic strategies, and they
support the occurrence of an intrinsic
vulnerability to stress. They also caution
that the appearance of morphological
changes does not always culminate in
motoneuron loss. These reports addition-
ally suggest a substantial prevalence of
gain-of-toxic and cell-autonomous mech-
anisms of neurodegeneration in ALS.
The current studies illustrate that the
use of combinatorial approaches to
study iPSC-derived motoneurons offers
a well-controlled cell culture model of
ALS. The identification of robust and
inherited morphological, biochemical,
and electrophysiological phenotypes in
iPSC-derived neurons supports and
sometimes contrasts with the well-estab-
lished animal models of the disease and
will open the possibility of developingnovel drug screenings with therapeutic
potential and the identification of novel
biomarkers of ALS. These advances will
also facilitate the future generation of
personalizedmedicine through the testing
of drugs to alleviate selective pathological
events that may be unique to the specific
genetic landscape of each patient, open-
ing important avenues for the treatment
of this fatal disease.ACKNOWLEDGMENTS
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In this issue, Chung et al. (2014) generate human embryonic stem cells by fusing an adult somatic cell to a
previously enucleated human oocyte, in agreement with recent reports by the Mitalipov and Egli groups.
We can now safely say that human somatic cell nuclear transfer is alive and well.Last year, the group led by Shoukhrat
Mitalipov published, for the first time,
their success in generating hESCs using
cloned human embryos (Tachibana et al.,
2013). The field of SCNT, launched by
Dolly in 1997, has since been developed
by the successful cloning of more than
twenty different mammalian species.
Using hSCNT to generate hESCs, how-
ever, turned out to be more challenging
(Cibelli et al., 2001; Fan et al., 2011; French
et al., 2008; Noggle et al., 2011; Stojkovicet al., 2005). Mitalipov’s group spent a
significant amount of time refining SCNT,
first with monkeys and then with humans.
As a result, we now know how to over-
come some fundamental roadblocks.
The study by Chung et al. (2014), pub-
lished in this issue along with a recently
published paper by Yamada et al. (2014),
brings to light fundamental aspects of
hSCNT, reasserting this technique as a
powerful research and therapeutic tool
(Chung et al., 2014; Yamada et al., 2014).Prior to the publication of this work
and based on studies comparing donor
nuclei from ESCs with those of somatic
cells, there was a general notion that
less differentiated cells would serve as
better sources of donor nuclei. Chung
et al.(2104) successfully dedifferentiated
somatic cells from a 75-year-old donor,
which is a landmark achievement that
refutes the hypothesis that cells from an
older individual are harder to dedifferen-
tiate. Borrowing from half a century’sll 14, June 5, 2014 ª2014 Elsevier Inc. 699
Figure 1. Streamlined Process for Somatic Cell Nuclear Transfer
with Human Cells
A list of steps that enabled a higher efficiency of the SCNT process in human.
Prior to 2013, these factors were individually tested in animal protocols. Iden-
tifying oocyte donors with oocytes endowed with the highest epigenetic power
to reprogram a somatic cell nucleus should be the next priority. If oocytes with
the described conditions were readily available, multiple autologous-ESC lines
could be produced by a single donor.
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Previewsworth of data on SCNT in
mammals, we can safely say
that the biological age of the
nuclear donor will not be a
limitation when it comes
to making autologous ESCs
by SCNT in humans. It re-
mains to be determined if
the variability on resistance
to nuclear reprogramming
observed in animal studies
between and within donor
cell types will influence the
efficiency of the procedure.
A successful SCNT proce-
dure, measured by the num-
ber of blastocysts or ESCs
produced, depends on multi-
ple factors. Among the most
important are oocyte quality,
type of enucleation used,
cell fusion, oocyte activation,
time of oocyte activation, cul-
ture medium, and type and
cell cycle stage of the donornucleus. The final efficiency is equal to
the cumulative efficiency of each step.
Once Tachibana et al. (2013) established
the protocol, Chung et al. (2014) were
able to dispel the notion that the human
egg was somehow deficient on two cen-
trosomal proteins and was inducing
aneuploidy in the embryos. They then
honed in on the time of activation after
fusion and demonstrated that waiting
2 hr is ideal. Their findings show that a
fundamental variable determining the
outcome of the procedure is the oocyte’s
cytosol and that only cohorts donated by
some women shared such favorable
cytosol. Independently of the age of the
somatic cell donor and of the period of
time preceding activation of the recon-
structed oocytes, the oocyte cytosol
from three of the seven women who
donated oocytes best supported embry-
onic development and ESC derivation.
This was suggested by Tachibana et al.
(2013)—eight oocytes donated by a
single woman produced four SCNT-
ESCs—and the current publication now
confirms it. Yamada et al. (2014) also
contribute more evidence that the
oocyte cytosol is a major variable and
point out that we must be extremely
careful during cell fusion not to induce
premature activation in the egg, a step
that was considered innocuous prior to
their work.700 Cell Stem Cell 14, June 5, 2014 ª2014 EIn most species, and humans are no
exception, the oocyte cannot divide by
itself without fertilization. Special proce-
dures are implemented during SCNT
to trigger embryonic development. The
challenge is to establish the most suitable
time point after fusion of the somatic cell
at which to activate development. Trig-
gering the activation of an MII oocyte
simultaneously with fusion is detrimental
to embryonic development. It is better to
‘‘marinate’’ the nucleus in an oocyte’s
cytosol before inducing egg activation.
Chung et al. (2014) built upon the method
reported by Mitalipov’s group (Tachibana
et al., 2013), demonstrating that the ideal
period is 2 hr. According to the results
reported in this issue, we can expect
that more blastocysts of better quality —
hatched and with a robust inner cell
mass — will be produced.
In trying to explain some of the differ-
ences that arise from fusing and activat-
ing the somatic cell at different times,
we must look closely at the early re-
programming events during SCNT. As
soon as the somatic cell nucleus comes
into contact with the MII oocyte’s cytosol,
nuclear envelope breakdown and chro-
matin condensation begin. Given enough
time, these early nuclear remodeling
events work in favor of somatic cell
dedifferentiation, but only to a point —
and how much is enough? Apparently,lsevier Inc.for humans and bovines,
2 hr is the Goldilocks point—
not immediately after fusion,
not 4 hr after—somewhere
around 2 hr works best (Liu
et al., 2013). If this is so, how
could Tachibana et al. (2013)
and Yamada et al. (2014)
generate cloned blastocysts
worthy of hESC isolation
without waiting 2 hr? The
answer to this riddle seems
to be in the use of histone
deacetylase inhibitors. It was
recently reported that rDNA
is not properly reactivated in
the genome of the somatic
cell and that this is directly
linked to histone acetylation.
The more quickly and effi-
ciently a pattern of embryonic
acetylated histones is estab-
lished, the greater the chan-
ces for normal development.
It turnsout that addinghistonedeacetylase inhibitors such as Trichos-
tatin A or scriptaid, a step that was
included in all three hSCNT-ESC reports,
can facilitate this process (Zheng et al.,
2012). It will be interesting to learnwhether
waiting 2 hr after fusion to activate the
egg, without using these compounds,
will yield high quality blastocysts as well.
Which is the SCNT variable, off all the
ones analyzed by these three excellent
manuscripts, that matters the most?
Where should we center our research
efforts? Identifying and characterizing
the oocyte’s cytosol with the strongest
epigenetic power to reprogram a somatic
cell nucleus must be our next priority
(Figure 1). In hindsight, the idea that
oocytes vary in this regard is not new. It
was first reported in 1991 by Latham and
Solter, who performed pronuclear ex-
changes between fertilized oocytes using
different strains of mice, but this process
was never tested in humans (Latham and
Solter, 1991). Yamada et al. (2014) andTa-
chibana et al. (2013) made some strides in
the right direction by showing correlations
between the hormonal regime used and
oocyte donor age with the developmental
potential of the oocytes; however, they
also presented contradictory evidence
about the importance of the number of
oocytes recovered per superovulation
cycle. For Tachibana et al. (2013), fewer
oocytes yielded better quality embryos,
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replicate the finding—one hSCNT-ESC
line was derived from an oocyte that was
picked from among 31 oocytes donated
at once by a single donor. Overall, these
data indicate that the oocyte cytosols of
different women differ in important ways
that go beyond the donors’ ages. Finding
the specific reason why some women
have better cytosol than others could
have a huge impact in the reprograming
field and, more importantly, in the ever-
growing field of human-assisted repro-
ductive technologies. To find the answers,
though, we will have to rely on SCNT, a
technique in which at least one variable,
the genomic DNA, is fixed; only then can
we really test the reprograming potential
of oocyte-cytosols from different women.
Human SCNT, a technique that not so
long ago was considered passe´, is nowback in the toolbox; this time, at least
for the task of finding the best human
egg, it will not be replaced by induced
pluripotent stem cells.
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Derivation of motor neurons from human pluripotent stem cells is inefficient and requires complex culture
protocols. Recently in Nature Materials, Sun et al. (2014) report that differentiating human pluripotent stem
cells on soft substrates increases the efficiency of mature motor neuron differentiation by altering cytoskel-
etal mechanotransduction through the Hippo/YAP/Smad pathway.Efficient derivation of motor neurons
(MNs) from human pluripotent stem cells
(hPSCs) is limited by our current under-
standing of the mechanisms underlying
MN differentiation as well as drawbacks
arising from inefficient and lengthy exist-
ing protocols. Human MNs derived from
in vitro cultures can be used for cellular
mechanistic studies as well as in vivo
studies testing cell replacement strate-
gies and modeling human disease in
animal models, with the ultimate goal of
replacing dysfunctional MNs in degenera-tive disorders like amyotrophic lateral
sclerosis. To enhance MN differentiation
and surmount some of these existing
difficulties, Jianping Fu and colleagues
(Sun et al., 2014) developed a mechanical
platform that enhances differentiation effi-
ciency of hPSCs into MNs by >4-fold and
significantly shortens the time period
required for MN maturation.
This platform capitalizes on advances
using micromolded poly-(dimethylsilox-
ane) (PDMS) micropost arrays (PMAs) to
culture cells (Fu et al., 2010). PDMS iswidely used to construct microscale de-
vices for cell culture and microfluidic
applications (Fu et al., 2010). PDMS sur-
faces are continuous and thus cannot
change rigidity without altering other
characteristics of thematerial. In contrast,
PMAs have a constant surface geometry
whose rigidity is varied by adjusting
heights of isolated microposts to cover
the stiffness range exhibited by soft
tissues without altering the contact
area available for cell-matrix interactions
or tethering of cell-surface integrins toll 14, June 5, 2014 ª2014 Elsevier Inc. 701
